Waiv

Waiv, based in France and formerly known as Owkin, is a spin-off from Owkin specializing in AI-driven precision testing solutions for digital pathology and oncology. The company offers advanced diagnostic tools to healthcare institutions and biopharmaceutical companies. Founded in 2026 by Meriem Sefta and headquartered in Paris, Waiv focuses on delivering AI-powered solutions in the healthcare sector. In March 2026, Waiv raised USD 33 million Series A funding co-led by new investors Alpha Intelligence Capital and OTB Ventures, with participation from other new investors 50 Partners, Karista, and Serena.

Other unspecified investors also participated in the round. Waiv specializes in AI-driven precision testing solutions aimed at enhancing digital pathology and oncology practices. The company’s flagship product, RlapsRisk BC, is clinically validated to unlock morphological insights and facilitate diagnostic workflows. It analyzes high-dimensional data to streamline biomarker discovery and supports multimodal diagnostic strategies.

Waiv serves a diverse clientele, including healthcare institutions and biopharmaceutical companies, which seek advanced diagnostic tools aligned with the shift towards precision medicine. The company operates in various international markets, particularly focusing on North America and Europe. Waiv generates revenue through structured partnerships and subscriptions with healthcare entities and biopharma companies. Clients engage with Waiv’s AI diagnostics services via tailored agreements for its flagship products like RlapsRisk BC.

Pricing plans vary according to the needs of healthcare providers, potentially including one-time fees for tests or ongoing subscriptions for a suite of solutions. Established collaborations with medical institutions further enhance its market presence and scalability in the evolving precision medicine landscape. In March 2026, Waiv raised USD 33. 00 mn in growth capital funding to support artificial intelligence-based oncology diagnostics and the development of its clinical test portfolio.

The company is focused on expanding its global operations and forming partnerships in pharmaceutical research. Upcoming initiatives include launching new products aimed at enhancing diagnostic capabilities in targeted markets by the end of 2026.